The use of the plasma protein Fetuin-B as a biomarker of therapeutic response under metformin in patients with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035981

Enrollment

Registered

2025-01-24

Start date

2021-04-19

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E28.2

Interventions

Group 1: PCOS-patients with metformin Examinations at inclusion: transvaginal ultrasound to determine PCO morphology of the ovary, oral glucose tolerance test (oGTT/insulin). Examinations at each stud

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: over 18, no desire to have children, PCOS dignosis according to ESHRE criteria, ability to give consent

Exclusion criteria

Exclusion criteria: No psychiatric illnesses, no serious illnesses that affect PCOS

Design outcomes

Primary

Measure	Time frame
Fetuin-B levels at t0 and t1	—

Countries

Germany

Contacts

Public ContactKonstantin Hofmann

Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Universitätsmedizin Mainz

konstantin.hofmann@unimedizin-mainz.de06131 17 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026